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Introduction 
For inherited genetic diseases, fetal gene therapy offers the potential of prophylaxis against 
early, irreversible and lethal pathological change. To explore this, we studied neuronopathic 
Gaucher disease (nGD), caused by mutations in GBA. In adult patients, the milder form 
presents with hepatomegaly, splenomegaly and occasional lung and bone disease; this is 
managed, symptomatically, by enzyme replacement therapy. The acute childhood lethal form, 
nGD is untreatable since enzyme cannot cross the blood brain barrier. nGD patients exhibit 
signs consistent with hindbrain neurodegeneration including neck hyperextension, strabismus 
and, often, fatal apnea 1. We selected a mouse model of nGD carrying a loxP-flanked 
neomycin disruption of Gba plus Cre recombinase regulated by the keratinocyte-specific K14 
promoter. Exclusive skin expression of Gba prevents fatal neonatal dehydration. Instead, 
mice develop fatal neurodegeneration within fifteen days 2. Using this model, fetal 
intracranial injection of adeno-associated virus (AAV) vector reconstituted neuronal GCase 
expression. Mice lived for up to at least 18 weeks, were fertile and fully mobile. 
Neurodegeneration was abolished and neuroinflammation ameliorated. Neonatal intervention 
also rescued mice but less effectively. As the next step to clinical translation, we also 
demonstrated the feasibility of ultrasound-guided global AAV gene transfer to fetal macaque 
brains.  
 
Main text 
Antibodies against activated microglia (CD68) and astrocytes (glial fibrillary acid protein, 
GFAP) were used to assess spatiotemporal neuroinflammation and gliosis in the nGD mouse 
and this was quantified by thresholding image analysis. Unlike wild types (WT) and 
heterozygotes, brains of symptomatic P12 knockouts exhibited significant and widespread 
microglial activation (Fig. S1C) particularly in the gigantocellular nucleus (Gi) of the 
brainstem, the ventral posteromedial and posterolateral thalamic nuclei (VPM/VPL) and layer 
V of the somatosensory barrel field cortex (Layer V S1BF). Blinded semi-quantitative 
scoring revealed that no region was spared (table S1). This was confirmed by 
immunostaining for a second microglial marker, Iba1 (Fig. S1F). Significant astrogliosis (Fig. 
S2C), was confirmed by both thresholding analysis and blinded scoring (table S2). At 
presymptomatic age P8, knockout mouse brains showed significant microglial (Fig. S1B) and 
astrocyte (Fig. S2B) activation in the thalamus and brainstem. Blinded scoring (tables S1 and 
S2) and Iba1 immunohistochemistry (Fig. S1E) provided confirmation. Remarkably, even in 
P1 neonates there was significant activation of astrocytes (Fig. 1A, 1B and 1C) and microglia 
(Fig. 1D. 1E and 1F) in the brainstem. 
 
Neuronal loss was quantified by stereological assessment of Nissl stained coronal sections. 
There was significant neuronal loss in the cortex, thalamus and brainstem of knockouts at 
P12 (Fig. S3B), accompanied by acellular spaces consistent with either large vacuole 
formation or lipid accumulation as determined by hematoxylin and eosin staining (Fig. S3C). 
In P8 knockouts there was significant loss of cortical and midbrain neurons (Fig. S3A). 
Neuronal loss correlated with microglial and astrocyte activation and, consistent with 
findings in a milder nGD model 3 there was significant cortical thinning in S1BF (Fig. S3D), 
however no difference in volume was observed (Fig. S3E).   
 
In the absence of functional GCase, its substrate, glucosylceramide (D-glucosyl-β1-1′-Nacyl-
D-erythro-sphingosine), and related sphingolipid species accumulate in both humans and 
mouse models 4. Total glucosylceramide and glucosylsphingosine are elevated >20 fold at 
birth in the nGD mouse 5, but no detailed measurements of different glucosylceramide 
species and proximal metabolites have been made. We assembled a temporal profile in whole 
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brain homogenates using liquid chromatography and tandem mass spectrometry. In 
knockouts all glucosylceramide species except for C24:0-OH and C24:1-OH were 
significantly elevated at P1, C18:0 and C16:0 being most abundant (Fig 1G and Fig. S4A); 
glucosylpsychosine was increased the most (table S3). At P8 and P12 these remained the 
most elevated in both absolute (Fig. S4B and S4C) and relative (table S3) terms. As expected, 
the gangliosides GM1a, GD1a, GD1b or GTb remained unchanged in knockouts irrespective 
of their age (fig S4D to S4F). 
 
The upregulation of neuroinflammatory markers and glycosphingolipids in P1 knockouts 
suggested that prophylactic in utero gene therapy might be beneficial. We selected adeno-
associated virus serotype 9 (AAV9) as we6, and others 7 have observed widespread neuronal 
expression of green fluorescent protein (GFP), following fetal intracranial injection. We 
examined the expression profile after fetal intracranial injection of an AAV9 vector encoding 
GFP driven by a β-glucuronidase (GUSB) promoter 8 (Fig. S5A). At 16 days gestation 
fetuses received 5 µl of AAV9 vector (5x1010 genome copies) into the lateral ventricle. At 30 
days of age, strong bilateral fluorescence extended from the olfactory bulbs to the brainstem 
(Fig. S5B). Bilateral homogeneity of expression and extensive spread from prefrontal cortex 
to cerebellum and brainstem was confirmed by immunohistochemistry (Fig. S5C). Many 
GFP-expressing cells with neuronal morphology were observed in the cortex, striatum, 
hippocampus, thalamus, cerebellum and, importantly, brainstem (Fig. S5D).  
 
Using the same vector configuration, mode and timing of injection we delivered human 
AAV9-GBA9 into pups of Gba heterozygous parents. Whilst impossible to genotype in utero, 
we identified three knockouts after birth by assay of GCase activity in blood spots obtained 
by superficial temporal vein puncture. They exhibited neither paralysis nor dyskinesia, 
remaining indistinguishable from WT littermates until sacrifice at 35 days of age. Treated 
knockouts had substantially diminished microglial and astrocyte activation versus untreated 
P12 knockouts in the prefrontal cortex, striatum, hippocampus and cerebellum (Fig. 2A and 
2B and Fig. S6A and S6B) and there was a tendency for greater treatment effects in Gi than 
S1BF (Fig. S6D and S6E). 
 
Lysosomal-associated membrane protein 1 (LAMP-1) is increased in fibroblasts of a patient 
with nGD 10, and was, therefore, selected as a more direct marker of lysosomal compartment 
size. P12 knockout brains showed strong LAMP-1 expression compared with P35 WT mice. 
In contrast, staining was similar in treated knockouts and WT mice, with the exception of 
few, sparse darkly stained LAMP-1 positive cells in treated knockouts (Fig. 2C and Fig. S6C) 
 
Gene therapy prevented neuronal loss in knockouts in the thalamus and Gi (Fig. 2D). Staining 
with two anti-GCase antibodies indicated that normal enzyme expression had been restored, 
yet each provided different insights. A C-terminus-specific antibody showed that WT and 
AAV9-treated knockouts exhibited discrete GCase immunoreactivity within neurons, that 
was completely absent in untreated knockouts. In contrast, an N-terminal antibody revealed 
strong staining of glia rather than neurons in all cortical layers, which was absent in WT 
brains. After AAV9 treatment of knockouts, staining was observed in neurons in the deeper 
cortical layers but not in glia (Fig. 2E).  
 
To test long-term efficacy, we injected five knockouts (two males and three females, three 
separate litters). Consistent with the description of the model 2, seven untreated control 
knockouts developed forelimb paralysis then tetraparesis; 5 and 2 mice were sacrificed at 
humane endpoints at 14 and 15 days of age. In contrast, at 70 days of age all treated 
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knockouts appeared normal and fertile, two were able to produce a litter of two symptomatic 
knockouts (movie S1). One treated mouse was culled at 125 days after exhibiting stereotypic 
circling behavior and another at 131 days because of an untreatable eye infection; at which 
time the remainder were then culled (Fig. 2F). GCase activity in brain homogenates of treated 
mice was not significantly different from WTs (Fig. 2G). Paradoxically, other parameters 
indicated only partial correction of disease phenotype. Treated knockouts tended to perform 
worse on rotarod (Fig. 2H) and grid walk (Fig 2I) tests. At 100 days they weighed 
significantly less than unaffected littermates (Fig. 2J) and appeared hyperkinetic (movie S2). 
They exhibited significant elevation of the shorter chain glycosphingolipids, 
glucosylpsychosine and lyso-lactosyl ceramide (Fig. 2K) and GD1a (Fig. S6G) but not 
glucosylceramide (fig S6H). Microglial activation (Fig. S6I) and astrogliosis (Fig. S6J) was 
ameliorated but not normalized and four of the five mice exhibited ventriculomegaly.  
 
To test efficacy of gene therapy later in development, newborn (P0-P1) knockouts received 
intracerebroventricular injection of 5µl AAV9 vector (5.0x1010 genome copies). Previous 
studies have demonstrated the ability of intravenous AAV9 to cross the blood-brain barrier of 
neonatal mice 11,12 and non-human primates 11 resulting in efficient expression in neural cells 
and viscera 13. Therefore, we also tested if an intravenous administration of the AAV9 vector 
(4x1011 genome copies) to knockouts could ameliorate both visceral and brain pathology. 
Both treated cohorts were rescued from neonatal death, exhibited neither paralysis nor 
dyskinesia and remained indistinguishable from WTs until sacrifice at 55 days of age (Fig 
3A). There were no significant differences in weight (Fig 3B) or motor co-ordination (Fig 
3C) between treated knockouts and WTs.  
 
There was significant supraphysiological expression of GCase in the cortical S1BF region, 
CENT2 of the cerebelleum and Gi, and physiological levels in the hippocampal CA1-CA2 
and thalamic VPM/VPL regions (Fig. 3D). There was no significant increase in astrogliosis 
the CA1-CA2, VPM/VPL and Gi of intravenously injected knockouts at 55 days (Fig. 3E) 
however there was a significant increase in the S1BF, VPM/VPL and CENT2 regions. There 
was no significant increase in microglial activation between the treated mice in any region 
except S1BF (Fig. 3F). Furthermore, the untreated 14 day old knockout nGD mice showed a 
significantly higher amount of staining compared to the older intravenously treated mice in 
the VPM/VPL and Gi regions. There was no significant increase in the lysosomal marker 
LAMP1 in any region except Gi (Fig. 3G). There was no significant loss of neurons in the Gi 
of knockouts mice treated with intravenous gene therapy (Fig. 3H). However, there was a 
significant loss in the cortical S1BF and thalamic VPM/VPL regions. The cortex was 
significantly thinner in intravenously-injected knockouts (Fig. 3H). Despite overall strong 
GCase staining in the S1BF region and the cerebral cortex neuroinflammation, neuronal loss 
and subsequent cortical thinning were still evident. 
 
After both intracerebroventricular and intravenous injection GCase was significantly elevated 
in visceral organs (Fig. 3I), suggesting vector escape from the brain after 
intracerebroventricular administration. Intravenous gene therapy normalized enzyme activity 
in all visceral organs except the heart where activity was supraphysiological. Intravenous 
gene therapy prevented splenomegaly (Fig. 3J) and Gaucher cell infiltration in spleen, liver 
and lungs. In contrast, intracerebroventricular injection failed to prevent Gaucher cell 
infiltration in spleen (Fig. 3K), liver (Fig. 3L) and lungs (Fig. 3M), as confirmed by 
immunohistochemistry.  Therefore, while intracerebroventricular gene therapy is effective in 
treating the lethal neuropathology, it does not ameliorate the visceral manifestations. 
5 
 
However, intravenous administration effectively limits both neurological and visceral 
pathology. 
 
Separate groups were assessed for long-term efficacy. All treated mice survived to at least 
180 days and were indistinguishable from age-matched WTs (Fig. 3N). Spleens from 
intracerebroventricular injection cohorts were significantly heavier than those receiving 
intravenous injection (Fig. 3P). Large Gaucher cells were present in the spleens following 
intracerebroventricular, but not intravenous injection (Fig. 3O).  
 
We next asked whether in utero gene delivery could achieve widespread expression in the 
larger, gyrencephalic primate brain by performing ultrasound-guided delivery of AAV9 
vectors to mid-gestation fetal macaques. Cerebrospinal fluid flows from the lateral ventricles 
through the ventricular system to the central canal of the spinal cord and the subarachnoid 
cisterns. Therefore, to achieve maximum vector spread, we identified the lateral cerebral 
ventricles of two-day 58 (0.4G) macaque fetuses by transabdominal ultrasound. Vector was 
injected into the right lateral ventricle under ultrasound guidance. scAAV9-GUSB-GFP was 
administered at a concentration of 6.6x1012vg/mL over 60 seconds. Correct delivery was 
confirmed by observation of transient (10 min) ventricular swelling (Fig4A). Both macaques 
presented normally at birth. There was extensive and bilateral rostro-caudal expression of 
GFP (Fig 4B) with numerous GFP-positive cells of neuronal morphology in the superior 
frontal and middle temporal gyri, thalamus, hippocampus, uvula and Gi (Fig 4C). Most other 
brain regions contained immunopositive cells except for, particularly, the caudate nucleus 
and putamen (Fig. S7). No discrete cells were observed in unstained brain (Fig 4B and 4C 
and Fig. S7). 
 
The sustained, widespread gene expression from a single vector injection is supported by a 
recent study in non-human primate studies and clinical trials. At least 15 years of AAV-
mediated transgene expression has been demonstrated in a non-human primate model of 
Parkinson’s Disease 14. Proof-of-concept has already been provided for single dose sustained 
long-term AAV expression in liver directed gene therapy for the treatment of hemophiliac 
patients 15.  
 
Widespread CNS gene delivery by fetal intracranial injection offers the best therapeutic 
potential for inherited early onset neurodegenerative diseases affecting the whole brain. 
Delivery to the developing CNS may be especially important since neurons have limited 
regenerative capacity. This is evidenced by the fact that neonatal vector delivery was less 
effective than fetal intervention in averting neuronal loss. Of several studies on in utero gene 
therapy in gene-disrupted mice 16, none involved models where pathology is already evident 
at birth and fetal intervention is the only tractable approach.  Recent gene therapy clinical 
trials for mucopolysaccharidosis type IIIa and spinal muscular atrophy 17 indicate that the 
youngest patients derived most therapeutic benefit 18. 
 
Normalization of GCase activity in the brain did not completely abolish pathology. 
Knockouts receiving intracerebroventricular injection developed visceral disease. 
Hypermetabolism, previously identified in Gaucher patients 19, may account for their lower 
body mass. However, this would not explain the failure to normalize brain 
glycosphingolipids, nor prevent long-term microglial and astrocyte activation and 
ventriculomegaly. AAV gene delivery follows a Poisson distribution 20. Therefore, individual 
neurons may receive variable gene dosage, with some remaining un-transduced, as evidenced 
by heterogeneous staining in treated knockout brains (Fig. 2E). 
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Human fetal gene therapy necessitates accurate prenatal diagnosis.  From cell-free fetal DNA 
in the maternal circulation, founder mutations underlying Gaucher disease can be detected 
non-invasively 21. Concerns over weak genotype-phenotype correlation can be mitigated: 
several lysosomal storage diseases, including Gaucher disease, have been diagnosed by 
enzyme assay of chorionic villi samples 22. Currently, prenatal screening is usually restricted 
to a family with a history of Gaucher disease or parents of an affected child, although 
advances in non-invasive prenatal diagnosis may help identify most cases.  
 
Perinatal gene transfer has been shown to reduce or avoid an immune response to either a 
protein, (absent in an animal model and potentially also in some patients), or to a viral capsid 
protein 23,24.  Immune tolerance may permit vector readministration. The presence of GCase 
in the skin of the knockout nGD mice precluded us from investigating this specifically. 
Nevertheless, immune tolerance towards a non-mammalian protein following fetal or 
neonatal gene delivery has been observed in non-human primate studies 25 and in mice this 
allowed effective re-administration of vector 26. Avoidance of an immune response following 
gene therapy is important. Non-human primates seropositive for AAV9 are less efficiently 
transduced using an AAV9 vector 27. Prednisolone was used in a recent AAV9 gene therapy 
clinical trial for spinal muscular atrophy to manage anti-vector immune responses 17. While 
this effectively managed the immune response, in utero administration of vector may pre-
empt exposure to WT AAV and thus development of anti-capsid immunity. 
 
This study highlights the potential of fetal gene therapy for neonatal lethal neurodegenerative 
diseases; the non-human primate data offers a clinically feasible protocol for its 
implementation. This, and other preclinical fetal gene therapy studies, address the suggested 
requirements of the NIH recombinant DNA advisory committee28, namely safety and efficacy 
in relevant models for progression to clinical trials. 
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Figure Legends 
 
Fig. 1. Brain disease at birth in nGD mice. (A) GFAP immunostaining in newborn knockouts, 
heterozygous and WT brains. Scale bar = 1mm (B) Higher magnification of (A) in the 
somatosensory barrel field cortex (S1BF), ventral posteromedial/posterolateral nuclei 
(VPM/VPL) and gigantocellular nucleus (Gi). Scale bar = 0.25mm. (C) Quantification of (B) 
(2-way ANOVA, Tukey’s multiple comparison). (D) CD68 immunohistochemistry in 
newborn knockout, heterozygous and WT brains. Scale bar = 1mm (E) Higher magnification 
of (D). (F) Quantification of (E) (2-way ANOVA). (G) Mass spectrometry analysis of 
glucosylceramide isoforms, glucopsychosine and lyso-lactosylceramide in knockouts, 
heterozygote and WT brains (2-way ANOVA on log-transformed data; Bonferroni’s multiple 
comparison). Numbers of mice are stated under each group. n.s. = not significant 
 
Fig. 2. Fetal gene therapy of nGD mice. (A) CD68, (B) GFAP and (C) LAMP1 brain 
immunostaining of untreated post-gestational day 12 (P12) knockouts and P35 WT and 
treated mice from different litters (scale bar = 1mm). (D) Stereological estimates of neuron 
number in the brains of treated knockout, heterozygote, WT and untreated day 12 knockouts 
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(2-way ANOVA, Bonferroni’s multiple comparison, all versus WT). (Representative of 3 KO 
replicates shown in Fig. S6) (E) GCase C-terminal antibody labelling neurons in WTs, 
knockouts and treated knockout brains. N-terminal antibody staining in WT and treated 
knockouts (S1BF images, scale bar = 0.25mm). Representative of 3 mice replicates per 
experimental cohort. (F) Survival studies of treated knockouts compared to untreated 
knockouts (Mantel-Cox test, n=5 and 7 mice, respectively). (G) GCase enzyme activity in 
treated and WT brains (Students one-tailed t-test). (H) Rotarod and (I) foot-fault tests on 
treated knockout and WT mice (2-way ANOVA, Bonferroni’s multiple comparison). (J) 
Weights of treated and WT mice over time (Students one-tailed t-test on weight at 100 days, 
WT n=19, KO n=5). (K) Mass spectrometry profiles in the brains of treated knockout and 
WT mice (2-way ANOVA on log-transformed data, Bonferroni’s multiple comparison). 
Numbers of mice are stated under each group. n.s. = not significant 
 
Fig. 3. Intracerebroventricular and intravenous gene therapy in neonatal nGD mice. (A) 
Kaplan-Meier survival plot of untreated knockouts, IC gene therapy treated knockouts, IV 
gene therapy treated knockouts and WTs (Logrank, Mantel-Cox test). (B) Weights of mice 
from (A). (C) Rotarod assessment of mice from (A) (repeated measures ANOVA). 
Immunohistochemistry for GBA1 (D), GFAP (E), CD68 (F) and LAMP1 (G) in brains of 55 
day old treated knockout and WTs and P12 untreated knockouts in the S1BF, hippocampal 
cornu ammonus 1 (CA1), the cerebellar central lobule II (CENT2) and Gi (2-way ANOVA, 
Tukey’s multiple comparisons). (H) Neuron counts in the Gi, S1BF and VPM/VPL in treated 
knockouts and WTs and cortical thickness measurements (2-way ANOVA, Tukey’s multiple 
comparisons). (I) GCase activity in organs of treated knockouts, WTs, and untreated P12 
knockouts (2-way ANOVA, Tukey’s multiple comparisons). (J) Spleen weights from mice 
receiving gene therapy and WTs (1-way ANOVA, Tukey’s multiple comparisons). 
Haemotoxylin and eosin staining and CD68 immunohistochemistry of (K) spleens, (L) livers 
and (M) lungs from intravenously and intracerebroventricularly gene therapy treated and WT 
mice (white arrows highlight Gaucher cells, scale bar = 0.1mm). (N) Kaplan-Meier survival 
plot of long-term gene therapy treated and untreated knockouts (Mantel-Cox test). (O)  CD68 
immunohistochemistry on spleens from (N) and WTs (scale bar = 0.25mm). (P) Spleen 
weights from (O) (1-way ANOVA, Tukey’s multiple comparisons). Numbers of mice are 
stated under each group. n.s. = not significant 
  
Fig. 4. In utero gene delivery to the macaque brain via ultrasound-guided 
intracerebroventricular injection of vector. (A) Ultrasound images following 
intracerebroventricular administration over time. (B) Green fluorescent protein 
immunohistochemistry on brain sections from administered macaques and control. Scale bar 
= 5mm. (C) Higher magnification examination of (B) Scale bar = 0.25mm. Representative of 
2 administered macaques replicates 
 
 
Online methods 
 
Animal welfare 
Mouse procedures and welfare was approved by the University College London Animal 
Welfare and Ethical Review Board (AWERB) and in accordance with project and personal 
licenses granted by the UK Home Office and the Animal (Scientific Procedures) Act of 1986. 
The mouse model for acute neuronopathic Gaucher disease used in this study has been 
previously described together with all genotyping procedures and primer sequences 2. Mice 
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heterozygous for mutation in the Gba1 gene and carrying the Cre recombinase gene on a 
C57BL/6 background were outbred onto wild type CD1 mice (Charles River, Harlow, UK) 
for five generations. The CD1 strain allows for larger litter size and excellent maternal care of 
pups. The colony was then maintained using breeding pairs heterozygous for the GBA 
mutation and carrying the Cre-recombinase gene. Macaque procedures and welfare were 
approved by and performed in accordance with the Institutional Animal Care and Use 
Committee (IACUC) at the National University of Singapore and Singapore Health Services 
Pte., Ltd (IACUC 2009-SHS-512). All in vivo studies performed in macaques were 
conducted at the SingHealth Experimental Medicine Centre that has been accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC). Potential dams were screened for pre-existing anti-AAV9 antibodies and 
seronegative females were time-mated. Pregnancies were confirmed, dated and monitored by 
ultrasound before and after vector delivery. 
 
Histological and immunohistochemical analyses 
Experimental cohorts of mice were culled by terminal transcardial perfusion using phosphate 
buffered saline (PBS), with the exception of P1 mice culled by decapitation. Macaque brains 
and spinal cords were harvested following euthanasia using isoflurane and pentobarbitone, 
cardiac puncture and perfusion of 1% paraformaldehyde. 
For free-floating immunohistochemistry-based analyses, the brains were removed and placed 
into 4% paraformaldehyde solution and stored for 48 hours at 4 oC before being 
cryoprotected in 30% sucrose for a minimum of 24 hours at 4 oC. The brains were then serial 
sectioned along the rostro-caudal axis at 40 μm thick sections using a freezing microtome 
(Thermo Fisher Scientific). Immunohistochemical staining was used to detect gene 
expression. Endogenous peroxidase activity was quenched by incubating sections in 1% 
H202 in TBS solution for 30 min. Following three washes in TBS, sections were incubated 
for 30 min in a solution of 15% normal serum in TBS-T (0.3% Triton X-100 in TBS). 
Subsequently sections were incubated at 4 °C overnight in primary antibody in TBS-
T/10% serum. After rinsing in TBS, the sections were incubated for 2 h in secondary IgG 
diluted in TBS-T/10% serum. Sections were then rinsed in TBS and incubated for 2 h in a 
1:1000 solution of Vectastain avidin–biotin solution (ABC; Vector Labs, Peterborough, 
UK). The sections were rinsed in TBS and incubated in 0.05% solution of DAB containing 
0.01% H202. The staining reaction was stopped by adding ice cold TBS. The sections were 
mounted onto chrome-gelatine-coated Superfrost-plus slides (VWR, Poole, UK) and left to 
air-dry overnight. The sections were dehydrated in 70% ethanol, cleared in xylene for 
30 min before being coverslipped using DPX mounting medium. This protocol was used 
with the following combinations of primary antibodies, blocking serum and secondary 
antibodies: Rat anti-mouse CD68 (1:100; AbD Serotec, MCA1957) 12, rabbit serum and 
rabbit anti-rat (1:1000; Vector Laboratories Inc.); mouse anti-GFAP (1:500; Millipore, 
MAB3402), goat serum and goat anti-mouse (1:1000; Vector Laboratories Inc.); rabbit anti-
LAMP1 (1:200; Abcam, AB24170), goat serum and goat anti-rabbit (1:1000; Vector 
Laboratories Inc.); mouse anti-GBA1 (N-terminus) (1:150; Origene, TA803361), goat serum 
and goat anti-mouse (1:1000; Vector Laboratories Inc.); rabbit anti-GBA1 (C-terminus) 
(1:1000; Sigma-Aldrich, G4171), goat serum and goat anti-rabbit (1:1000; Vector 
Laboratories Inc.); rabbit anti-GFP (1:10,000; Abcam, AB290), goat serum and goat anti-
rabbit (1:1000; Vector Laboratories Inc.), respectively. Brain sections were Nissl stained 
using cresyl violet. The sections were incubated in 0.05% cresyl violet in 0.05% acetic acid 
for 30 mins at 60 oC and then washed in de-ionised water. The sections were differentiated 
through ascending concentrations of alcohol before being cleared in xylene and coverslipped 
with DPX. 
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For histology and immunohistochemical staining on paraffin-embedded tissue sections, mice 
were culled by transcardial perfusion as described above. Brain fixed in 10% buffered 
formol-saline was embedded in paraffin wax. Microglial activation was examined using an 
ionized calcium binding adaptor molecule 1 (Iba1) antibody (Wako Pure Chemical Industries, 
Ltd, 019-19741). Immunohistochemistry was performed on automated 
immunohistochemistry staining machines (Ventana Medical Systems Inc., Tucson, Arizona) 
using proprietary secondary detection reagents (Ventana Medical Systems Inc.) before 
development with 3′3-diaminobenzedine tetrachloride as the chromogen. Conventional 
methods were used for Harris haematoxylin and eosin staining. Sections were mounted on 
chrome-gelatine coated slides and air dried overnight. The sections were stained protected from 
light with filtered 0.1% Mayer Hematoxylin (Sigma-Aldrich) for 10 min. The slides were rinsed 
in distilled water for 5 min and consequently dipped 12 times in 0.5% Eosin solution. The 
sections were quickly washed in distilled water and subsequently dehydrated for 30 s in rising 
concentrations of ethanol (50%, 70%, 95%, 100%). The slides were finally incubated in Histo-
clear for 30 min and coverslipped with DPX mountant medium. 
 
Quantitative analysis of histological and immunohistochemical staining 
The quantification of immunohistochemical staining within discrete regions of the brain was 
conducted by a user blinded to the experimental cohorts. 40 non-overlapping RGB images 
were taken at x40 magnification through four consecutive sections within each region of 
interest. During image capture all camera and microscope settings were maintained. Regional 
areas of immunoreactivity were analysed by optical segmentation using Image Pro-Plus 
(Media Cybernetics). The foreground immunostaining was defined by averaging of the 
highest and lowest signals and the threshold was set and remained unchanged as each 
consecutive image was analysed. The data is represented as the mean percentage area of 
immunoreactivity per field for each discrete region. Stereological counts of neurons by 
optical fractionation and measurement of cortical thickness and volume was performed using 
Stereo Investigator (MBF Biosciences) 29. The grid size and the counting frame used for 
analysing different brain regions were the following: S1BF 150 x 150 μm, 50 x 50 μm; 
VPM/VPL 175 x 175 μm, 50 x 50 μm; Gi 100 x 100 μm, 50 x 50 μm. Cells were counted using a 
100X objective. Efficient sampling was estimated by a coefficient of error between 0.05 and 0.1 
30. 4 sections for each brain were analysed and the average values of cell counting were used in 
the calculations.  
The mean thickness of the S1BF cortical region was estimated by using the Cavalieri vertical 
sections principle 31. The length of 10 parallel consecutive lines intersecting perpendicularly the 
cerebral cortex, traced from the somatosensory barrel cortical layer 1 to the corpus callosum, was 
measured. 3 sections of the midbrain region per each brain were analysed and the average values 
were reported. 
 
Mass spectrometry 
Mouse brains were homogenised in water using an Ultraturax T25 probe homogeniser (IKA, 
Germany). Protein concentrations were determined using bicinchoninic acid (BCA) assay and 
200µg were analyzed for glucosylceramide, glucosylpsychosine and lyso-lactosyl ceramide 
accumulation. The substrates were extracted in 1ml of chloroform/methanol (2:1 v/v) 
containing 80µg/ml of d4-C16:0-glucosylceramide internal standard which was synthesized 
in house 32. The samples were shaken for 30 min at room temperature before the addition of 
200µl of PBS for phase separation. After a 10 min centrifugation at 16,000 g upper and lower 
phases were collected and 5 µl of each were injected into the ultra-performance liquid 
chromatography – tandem mass spectrometry (UPLC-MS/MS) system. Glycosphingolipid 
reference standards (Matreya, USA) was also analyzed to confirm analyte identity.   
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The samples were injected onto Waters ACQUITY UPLC system (Manchester, UK) operated 
in partial loop mode and separated on Waters ACQUITY UPLC BEH C18 column (130Å, 
1.7 µm, 2.1 mm X 50 mm) under the following gradient conditions: 0.00-0.20→80%A; 0.20-
5.00→0.1%A; 5.00-9.00→0.1%A; 9.01-11.00→80%A, where mobile phase A was ddH2O 
[0.1% FA]; phase B was methanol and the flow rate was 0.65 ml/min. Column and sample 
temperatures were kept at 40°C and 10°C respectively. Weak wash solvent was ddH2O [0.1% 
FA] and strong wash solvent was acetonitrile: methanol:isopropanol:ddH2O (1:1:1:1 v/v). 
The eluting analytes were detected on a Waters XEVO TQ-S triple quadrupole mass 
spectrometer (Manchester, UK) which was equipped with the electrospray ion source and 
operated in multiple reaction monitoring (MRM) and positive ion mode (see table S4 for 
MRM details) with the tune page parameters set to achieve the maximum sensitivity for 
glycosphingolipids as described previously 33. The data was processed with MassLynx v4.1. 
 
GSL Analysis 
Glycosphingolipids (GSLs) from brain homogenates were extracted with chloroform:methanol 
(1:2, v/v) overnight at 4°C and further purified using solid-phase C18 columns (Telos, Kinesis, 
UK). GSLs were dried down under nitrogen and treated with either Cerezyme® (Genzyme, 
Cambridge, MA) to obtain glucose from GlcCer, or ceramide glycanase (prepared in house 
from the medicinal leech Hirudo medicinalis/verbena) to obtain oligosaccharides from other 
GSLs. Liberated glucose and free glycans were then fluorescently-labelled with anthranillic 
acid (2AA). Excess 2AA label was removed using DPA-6S SPE columns (Supelco, PA, USA). 
Purified 2AA-labelled glucose and 2AA-labelled glycans were separated and quantified by 
normal phase high-performance liquid chromatography (NP-HPLC) 34. The NP-HPLC system 
consisted of a Waters Alliance 2695 separations module and an in-line Waters 2475 multi λ-
fluorescence detector set at Ex λ360nm and Em λ425nm. The solid phase used was a 4.6 x 
250mm TSK gel-Amide 80 column (Anachem, Luton, UK). Results were normalized to protein 
content determined using bicinchoninic acid (BCA) assay. 
 
Self-complementary AAV Vectors 
The human GBA1 cDNA was generated by polymerase chain reaction, verified by DNA 
sequencing and cloned into the Topo plasmid vector (Invitrogen, Carlsbad, CA). A 1.6 kb 
fragment (containing the open reading frame of the human GBA1 cDNA and bovine growth 
hormone polyadenylation signal sequence) was then generated by digesting the plasmid with 
the restriction enzymes NcoI and SpeI and subcloned into a shuttle plasmid containing the 
scAAV2 inverted terminal repeats (ITR) and the 0.4 kb GUSB promoter 35 (Fig. S8). 
Recombinant AAV9 serotype vectors encoding GBA1 (scAAV9-GUSB-GBA1) were 
generated by the standard triple plasmid transfection method as described previously 36. 
Briefly, cell lysates of transfected 293 cells were clarified by centrifugation and then purified 
by subjecting the preparations to two cycles of density gradient ultracentrifugation using 
cesium chloride. The purified recombinant vectors were re-suspended and stored in 10 mM 
sodium phosphate buffer, pH 7.3, containing 180 mM sodium chloride, and 0.001% pluronic 
F68.  
 
AAV Administrations to mice and macaques 
For marker gene studies we injected CD1 outbred mice. nGD mice were backcrossed onto the 
CD1 background, to maximize litter sizes and minimize risk of cannibalization. 
We have previously described the administration of gene delivery vectors to the brains of 
fetal mice 37 and intracerebroventricular injections to neonates has been described 38. We 
have previously described intravenous administration to neonatal mice 12. Briefly, pregnant 
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mice carrying pups at 16 days gestation were anaesthetized using isoflurane inhalation 
anaesthesia and a midline laparotomy was performed to expose the uterus. 5μl of AAV vector 
(5x1010 genome copies) was administered to all fetuses per dam via a transuterine injection 
targeting the anterior horn of the lateral ventricle of the left hemisphere of the brain. The 
laparotomy was sutured and mice were provided topical and systemic analgesia and allowed 
to recover in a warm chamber. The same dose was administered via intracerebroventricular 
injection to P0 neonates. The intracerebroventricular injections were directed to the anterior horn 
of the lateral ventricle. The injection site was identified at 2/5 of the distance from the lambda 
suture to each eye. P0-1 mice were anesthetised on ice for 30-60 seconds. A 33-gauge needle 
(Hamilton) was inserted perpendicularly at the injection site to a depth of 3mm and 5μl of vector 
was slowly administered. The pup was allowed to recover and placed back into the cage. 40μl of 
AAV vector (4x1011 genome copies) of vector was administered P0 neonates by injection of 
the superficial temporal vein. At postnatal day 0-1 pups were anesthetised on ice for 30-60 
seconds and intravenous injections were performed via the superficial temporal vein using a 33-
gauge needle (Hamilton). Once the needle was slowly removed, gentle pressure was applied to 
the injection site. When the pup fully recovered it was returned to the dam. 
Cynomolgus macaques (Macaca fasicularis) were used for non-human primate studies. 
Macaques underwent time-mating and pregnancy confirmed through ultrasound evidence of 
fetal pole and fetal heart activity. Dating of pregnancy was performed as previously reported 
(Mattar et al Mol Therapy 2011), and IUGT was performed at 0.4G. After induction of 
anaesthesia via sevoflurane, a 25G Quincke needle (Becton-Dickenson) was used to target 
the lateral ventricle closest to the anterior maternal abdomen under continuous ultrasound 
imaging. Vector was injected as a slow bolus (200-350μl to deliver a total dose of 1.3x1012vg 
and 2.3x1012vg in each fetus respectively) with ventricular swelling observed as evidence of 
correct delivery. The needle was removed immediately and the fetus monitored for a further 
15 minutes. A male fetus was delivered naturally and a female fetus was delivered by 
caesarean section and hand-reared as previously reported. Euthanasia and organ harvest was 
performed on days 0 and 6 respectively under ketamine and isoflurane, via cardiac puncture 
and exsanguination as previously described 39.  
 
 
 
Mouse behavioural studies 
Mice underwent foot-fault testing (adapted from Lubics et al 40) and Rotarod testing (adapted 
from Carter et al, 41) at P35, P73 and P100. The operator was blinded to the genotype of the 
animals throughout the testing period. Briefly, foot-fault testing involved placing a mouse on 
a stainless steel grid (41 x 25cm) with a mesh size of 1 x 1 cm, elevated 30cm above the 
bench surface. The number of times a limb fell through the grid (a foot-fault) within 30 
seconds was recorded. Rotarod testing employed a commercially available rotarod (Harvard 
Apparatus, Cambridge, UK). Mice were placed on the rotating drum under continuous 
acceleration (from 4-40rpm over 5 minutes), with the latency to fall from the rod, and the 
speed at which this occurred, measured. Any passive rotations were also noted. 
 
Stereoscopic fluorescence microscopy 
GFP expression in various organs was visualized with a stereoscopic fluorescence 
microscope (MZ16F; Leica, Wetzlar, Germany). Representative izmages were captured with 
a digital microscope camera (DFC420 Leica, Wetzlar, Germany) and image analysis software 
(LAS 4.2; Leica, Wetzlar, Germany). Because of the differences in the sizes of the organs, 
intensity of signal, and distribution of cells of interest, the images captured were optimized 
for exposure length and brightness in each case. 
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GCase Enzyme Assay 
GCase activity was determined using the established synthetic substrate, 4-
methylumbelliferone- β -glucopyranoside protocol as previously described 42. Frozen tissue 
samples were homogenized with distilled water on ice and the total protein concentration was 
measured using BCA assay. Samples were incubated with the substrate for 2 hours at 37 oC. 
The reaction was stopped with 1M glycine buffer, pH 10.4. Fluorescence of the standard 1nM 
4-methylumbelliferone and the samples was read (FluoStar Optima Plate Reader. Excitation 
wavelength: 360nm; emission wavelength: 450nm). The enzymatic activity (nmol/hr/μ) was 
calculated. 
 
Sample sizes, statistics and randomization 
Since the genotypes of injected mice could not be ascertained until after birth, the initial 
sample size was determined by the number of knockout pups in the uteri of three randomly-
selected pregnant dams. For most analyses, one-way or two-way analysis of variance 
(ANOVA) was performed with either Bonferroni or Tukey’s multiple comparison. The F 
statistic, underlying ANOVA is tolerant of violations in normality, for which we did not test. 
Nevertheless, mass spectrometry data, which was clearly not normally distributed, was 
converted by log transformation before ANOVA. Each experiment was performed only once. 
Behavioral and semi-quantitative scoring were blinded to the investigator. 
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Supplementary Fig. 1. Microglia-mediated inflammation in nGD mice.
CD68 immunohistochemistry and quantication on brain sections from wildtype, heterozygous and knockout mice at P1 (A), P8  (B) and P12 (C). Whole 
brain scale bar = 1mm; high magnication sections scale bar = 0.25mm,  (2-way ANOVA, Tukey’s multiple comparison). Scale bars = 0.25mm. (D) Iba1 
immunohistochemistry at P1, at P8 (E), and P12 (F) in sagittal paran embedded sections. Whole brain scale bar = 0.5mm; high magnication sections 
scale bar = 40μm. Numbers of mice are stated under each group. n.s. = not signicant
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Supplementary Fig. 2. Astrogliosis in nGD mice.
GFAP immunohistochemistry and quantication on brain sections from wildtype, heterozygous and knockout mice at P1 (A), P8  (B) and P12 (C). 
Whole brain scale bar = 1mm; high magnication sections scale bar = 0.25mm (2-way ANOVA, Tukey’s multiple comparison, n=4-5 mice). Scale 
bars = 0.25mm. Numbers of mice are stated under each group. n.s. = not signicant
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Supplementary Fig. 3. Histological and stereological analysis of nGD mouse brains.
Stereological counts of neurons in brain sections from (A) P8 and (B) P12 knockouts, heterozygous and wildtypes (2-way ANOVA, Tukey’s 
multiple comparison). (C) Haematoxylin and eosin staining of P1, P8 and P12 brains. Whole brain scale bar = 0.5mm; high magnication sections 
scale bar = 40μm.  (D) Cortical thickness and (E) cortical volume measurements from P12 mice (Students one-tailed t-test). Numbers of mice are 
stated under each group. n.s. = not signicant
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Supplementary Fig. 4. Metabolite and glycosphingolipid profile analysis of nGD mouse brains.
(A) Mass spectrometry of P1, (B) P8 and (C) P12  brains from knockout, heterozygous and wildtype mice (2-way ANOVA on log-transformed data, 
n=5 vs. 6 mice; Bonferroni’s multiple comparison). The glycosphingolipid proles of GM1a, GD1a, GD1b and GT1b were measured in (D) P1, (E) 
P8 and (F) P12 brains (2-way ANOVA on log-transformed data, n=5 vs. 6 mice; Bonferroni’s multiple comparison). Numbers of mice are stated 
under each group. n.s. = not signicant
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Supplementary Fig. 5. Fetal gene delivery marker gene studies in wild type mice.
(A) An illustration of the self-complementary genome conguration of AAV9-GUSB-GFP. The expression cassette contained the beta-glucuronidase 
promoter driving expression of the GFP gene followed by a polyadenylation signal. The expression cassette was anked by the viral inverted termi-
nal repeats. (B) Green uorescent protein in administered brains (o-olfactory bulbs, b-brainstem, c – cerebellum). Low (C) and high (D) magnication 
images following anti-GFP immunohistochemistry of free-oating brain sections. Whole brain scale bar = 1mm; high magnication sections scale 
bar = 0.25mm. Representative of 3 administered and unadministered mice replicates. (E) Plasmid map of AAV9-GUSB-GBA.
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Supplementary Fig. 6. Fetal gene therapy of nGD mice neuropathology.
 (A and D) CD68, (B and E) GFAP and (C and F) LAMP1 immunostaining on brain sections of P12 untreated knockouts, P35 wildtypes and hetero-
zygous and gene therapy treated knockouts. Scale bars = 0.25mm. Representative of 3 mice replicates per experimental cohort. (G) Analysis of 
GSLs in treated mice and control wild types, (2-way ANOVA on log-transformed data; Bonferroni’s multiple comparison). (H) Glucosylceramide 
levels in the brains of treated knockouts and wildtypes from long term studies (Students one-tailed t-test, n=5 mice). (I) CD68 and (J) GFAP 
immunostaining on brain sections from long term treated knockouts and wild type mice (all replicates shown). Numbers of mice are stated 
under each group. n.s. = not signicant
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Supplementary Fig. 7
Supplementary Fig. 7. Fetal gene delivery marker gene studies in macaques.
GFP immunohistochemistry to detect cells transduced with scAAV9-GUSB-GFP following ultrasound-guided intracerebroventricular injection of 
to the fetal macaque. Scale bar = 0.25mm. Representative of two replicates.
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TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGC 
GTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGA 
GAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGC 
TGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTCGAGCTCGGTACCTCGCGAATGCATCTAGAGGCCACTC 
CCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGA 
GTGGCCAACTCCATCACTAGGGGTTCCTGGAGGGGTGGAGTCGTGACAGATCTGAATTCCTGCTGGGAAAAGCAAGTGGAGGTGCTCCTTGAAGAAACAGGGGGATCCC 
ACCGATCTCAGGGGTTCTGTTCTGGCCTGCGGCCCTGGATCGTCCAGCCTGGGTCGGGGTGGGGAGCAGACCTCGCCCTTATCGGCTGGGGCTGAGGGTGAGGGTCCCG 
TTTCCCCAAAGGCCTAGCCTGGGGTTCCAGCCACAAGCCCTACCGGGCAGCGCCCGGCCCCGCCCCTCCAGGCCTGGCACTCGTCCTCAACCAAGATGGCGCGGATGGC 
TTCAGGCGCATCACGACACCGGCGCGTCACGCGACCCGCCCTACGGGCACCTCCCGCGCTTTTCTTAGCGCCGCAGACGGTGGCCGAGCGGGGGACCGGGAAGCATGG 
CCCGGGCTGCAGCTCTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTCTCTCTTTTAGATTCCAACCTTTGGAACTCAATTCAGCCA 
CCATGGCTGGCAGTCTTACAGGTCTCCTGCTCCTGCAAGCTGTCTCTTGGGCTTCTGGGGCCAGGCCCTGTATCCCCAAATCCTTTGGATACTCATCTGTGGTGTGTGTTTG 
TAATGCCACTTATTGTGATAGCTTTGACCCCCCCACCTTTCCTGCACTGGGCACCTTTTCAAGGTATGAATCTACCAGGTCTGGGAGGAGGATGGAGCTGAGTATGGGGCC 
CATCCAAGCAAACCATACTGGCACTGGCTTGCTGCTGACACTGCAACCTGAACAGAAGTTCCAGAAAGTGAAGGGCTTTGGAGGAGCCATGACTGATGCTGCTGCCCTC 
AATATTTTGGCCCTGAGCCCCCCTGCTCAGAATCTCCTTTTGAAATCATACTTCTCTGAGGAGGGAATTGGATACAATATCATCAGGGTGCCAATGGCCTCATGTGACTTTAG 
TATTAGGACTTACACCTATGCTGATACCCCTGATGATTTCCAGCTGCATAACTTCTCATTGCCTGAGGAGGATACCAAATTGAAGATCCCACTCATTCACAGGGCCCTGCAAC 
TGGCTCAGAGACCAGTGTCATTGCTGGCCTCCCCCTGGACCTCCCCAACTTGGCTCAAAACCAATGGGGCTGTCAATGGTAAGGGCTCTCTTAAGGGGCAGCCTGGAGAC 
ATTTACCATCAGACCTGGGCCAGGTATTTTGTGAAGTTCCTGGATGCTTATGCTGAGCACAAATTGCAATTTTGGGCTGTTACAGCTGAGAATGAACCCTCTGCAGGACTG 
CTGTCTGGCTATCCTTTCCAGTGCCTGGGCTTTACCCCTGAGCATCAGAGGGATTTCATTGCCAGGGACCTGGGACCTACTCTTGCCAATAGCACACACCATAATGTGAGG 
CTTCTGATGCTTGATGACCAGAGACTTCTGCTGCCACACTGGGCCAAGGTTGTCCTGACAGATCCTGAGGCTGCCAAGTATGTTCATGGGATTGCTGTGCACTGGTATCTG 
GACTTCCTTGCTCCAGCTAAGGCCACCCTGGGAGAAACACACAGGTTGTTTCCCAATACAATGCTTTTTGCATCAGAGGCCTGTGTGGGCAGTAAATTTTGGGAGCAGTC 
TGTTAGGCTGGGGAGCTGGGATAGAGGAATGCAATACTCCCATTCTATCATCACCAATCTGCTCTACCATGTGGTGGGGTGGACTGACTGGAACCTTGCCCTTAACCCTGA 
GGGTGGCCCCAATTGGGTCAGGAATTTTGTGGATAGTCCCATCATTGTGGATATCACCAAGGACACATTCTATAAGCAACCAATGTTCTATCACCTGGGTCACTTTAGTAAGT 
TTATCCCTGAGGGGTCCCAGAGGGTGGGACTGGTGGCTTCCCAGAAGAATGATCTGGATGCTGTGGCCCTGATGCACCCTGATGGCAGTGCTGTGGTTGTTGTTCTCAATA 
GAAGCTCTAAAGATGTGCCCTTGACCATCAAAGATCCAGCTGTGGGATTTCTGGAAACAATTTCCCCTGGTTATAGCATCCACACTTACCTTTGGAGAAGGCAGTGAAAAT 
GAAGGCCTGATAATTGCACCACCAGGCCTGATAGGCCCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTC 
CCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAA 
GACAATAGCAGGCATGCACTAGTCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCA 
GTGAGCGAGCGAGCGCGCAGAGAGGGATCTAGATATCGGATCCCGGGCCCGTCGACTGCAGAGGCCTGCATGCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTG 
TGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCAC 
TGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACT 
GACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAG 
CAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAG 
GTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTC 
CCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGAC 
CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGC 
GGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAG 
CTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTAC 
GGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCA 
ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTC 
GTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCC 
GGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAAC 
GTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCA 
AAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCC 
GTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCAC 
ATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCA 
ACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACT 
CATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTT 
CCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTC
Supplementary Fig. 8. Sequence of scAAV9-GUSB-GBA
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Supplementary Table 1
Supplementary Table 1. Scoring of CD68 immunohistochemistry in the nGD mouse model.
Discrete areas of the brain in knockout, wild type and heterozygous mice were scored at P1, P8 and P12. A scale of - to ++++ was used, where - 
= no activated microglia visible and ++++ was area densely populated with activated microglia.
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Supplementary Table 2
Supplementary Table 2. Scoring of GFAP immunohistochemistry in the nGD mouse model.
Discrete areas of the brain in knockout, wild type and heterozygous mice were scored at P1, P8 and P12. A scale of - to ++++ was used, where - 
= no activated astrocytes visible and ++++ was area densely populated with activated astrocytes.
Fold change in glycosphingolipids, KO/WT
Supplementary Table 3
P1 P8 P12
C16:0 21 4 13
C16:0-OH 12 2 4
C18:0 22 4 6
C18:0-OH 10 1 2
C20:0 8 2 5
C20:0-OH 10 1 1
C22:0 5 1 2
C22:0-OH 7 1 2
C24:1 13 1 1
C24:0 8 1 1
C24:1-OH 1 1 1
C24:0-OH 1 1 1
Glucosylpsychosine 524 216 485
Lysolactosyl ceramide 15 6 14
TSupplementary Table 3. Fold change in glycosphingolipids.
Glycosphingolipid MRM transitions
Supplementary Table 4
Glycospingolipid name 
Precusor 
m/z 
Fragment 
m/z 
Cone 
(V) 
Collision 
(V) 
 462.4 264.3 74 16 
lyso-lactosyl ceramide
glucosylpsychosine
 624.6 264.4 18 20 
C16:0 glucosylceramide 722.6 560.6 130 40 
d4C16:0 glucosylceramide 726.6 564.7 130 38 
C16:0-OH glucosylceramide 738.6 264.3 130 32 
C18:0 glucosylceramide 750.6 588.6 130 38 
C18:0-OH glucosylceramide 766.6 264.3 130 32 
C20:0 glucosylceramide 778.6 616.7 132 42 
C20:0-OH glucosylceramide 794.6 264.3 132 36 
C22:0 glucosylceramide 806.7 644.7 130 38 
C22:0-OH glucosylceramide 820.7 658.8 130 52 
C24:1 glucosylceramide 832.7 670.7 130 52 
C24:0 glucosylceramide 834.7 672.7 130 42 
C24:1-OH glucosylceramide 848.7 686.7 130 42 
C24:0-OH glucosylceramide 850.8 688.9 130 42 
Supplementary Table 4. Details of multiple reaction monitoring (MRM).
